Search Results
Your search for Matthew Stenger matches 212 pages
Showing 51 - 100Survival With Brachytherapy-Based Radiotherapy or Radical Prostatectomy in High-Risk Localized Prostate Cancer
In a study of National Cancer Database data reported in the Journal of Clinical Oncology, Ennis et al found no significant survival differences between patients receiving brachytherapy-based radiotherapy vs radical prostatectomy in men with high-risk localized prostate cancer. Study Details The...
SPARTAN Trial: Metastasis-Free Survival in Nonmetastatic Castration-Resistant Prostate Cancer
As reported by Smith et al in The New England Journal of Medicine, the phase III SPARTAN trial has shown that the androgen receptor inhibitor apalutamide (Erleada) produces significant improvement in metastasis-free survival and time to symptomatic progression vs placebo among men with...
Long-Term Survival Outcomes With Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Analysis of long-term survival outcomes in the phase III CHAARTED trial showed a survival advantage with the addition of docetaxel to androgen-deprivation therapy (ADT) in patients with hormone-sensitive metastatic prostate cancer, although no advantage was observed among patients with low-volume...
Patient-Reported Outcomes With Addition of Combination Treatment to ADT in Newly Diagnosed Metastatic Castration-Naive Prostate Cancer
As reported by Chi et al in The Lancet Oncology, the addition of abiraterone and prednisone to androgen-deprivation therapy (ADT) in the phase III LATITUDE trial was associated with improved patient-reported outcomes in patients with newly diagnosed metastatic castration-naive prostate cancer. The...
CTC Number May Be Marker of Improved Survival in Metastatic Castration-Resistant Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Heller et al identified two circulating tumor cell (CTC) markers that had high discriminatory ability for improved survival in metastatic castration-resistant prostate cancer. Study Details The study used individual patient data from 5...
PSA at 7 Months and Prognosis in Metastatic Hormone-Sensitive Prostate Cancer Treated With ADT With or Without Chemotherapy
In a study reported in the Journal of Clinical Oncology, Harshman et al found that a prostate-specific antigen (PSA) level ≤ 0.2 ng/mL at 7 months after the start of androgen-deprivation therapy (ADT) was significantly associated with longer overall survival in metastatic...
PARP1 and Androgen Receptor Inhibition in Metastatic Castration-Resistant Prostate Cancer
In a phase II trial (NCI 9012) reported in the Journal of Clinical Oncology, Hussain et al found no benefit of adding PARP1 inhibition with veliparib to abiraterone (Zytiga) plus prednisone in patients with metastatic castration-resistant prostate cancer. ETS fusion status was not predictive of...
Bipolar Androgen Therapy After Progression on Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
In a single-center phase II study reported in The Lancet Oncology, Teply et al found that bipolar androgen therapy can induce prostate-specific antigen (PSA) response and resensitization to enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer who progressed on...
Surveillance vs Metastasis-Directed Therapy in Recurrent Oligometastatic Prostate Cancer
In a Belgian phase II study reported in the Journal of Clinical Oncology, Ost et al found that androgen deprivation therapy (ADT)-free survival was prolonged with metastasis-directed therapy vs surveillance in recurrent oligometastatic prostate cancer. Study Details Sixty-two patients with...
Study Finds Racial Disparities in Treatment of Clinically Significant Prostate Cancer
In a study reported in the Journal of Oncology Practice, Bickell et al found underuse of treatment for clinically significant prostate cancer was infrequent among white and black patients at two New York City hospitals, but black men accounted for nearly all such underuse of treatment. As noted by...
Novel Clinical-Genomic Risk Group Classification for Localized Prostate Cancer
As reported in the Journal of Clinical Oncology, Spratt et al have developed an integrated clinical-genomic risk classifier for predicting distant metastasis in patients with localized prostate cancer. The classifier uses National Comprehensive Cancer Network® (NCCN) risk categories and risk...
HSD3B1 Variant and Response to Nonsteroidal CYP17A1 Inhibition in Castration-Resistant Prostate Cancer
As reported in JAMA Oncology by Almassi et al, extragonadal androgen ablation with the nonsteroidal CYP17A1 inhibitor ketoconazole improved outcome in men with metastatic castration-resistant prostate cancer according to the number of inherited HSD3B1 (1245C) alleles. HSD3B1 (1245C) is associated...
HSD3B1 Genotype and Outcomes With ADT After Radiotherapy for Localized Prostate Cancer
In a study reported in JAMA Oncology, Hearn et al found that the presence of the HSD3B1 (1245C) allele was associated with more rapid development of metastases in patients receiving androgen-deprivation therapy for biochemical recurrence after primary radiation therapy for localized prostate...
Combination Therapy for Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer
The phase III AFFINITY trial has shown no survival benefit with the addition of the antisense oligonucleotide custirsen to cabazitaxel (Jevtana)/prednisone in patients with metastatic prostate cancer previously treated with docetaxel. These findings were reported in The Lancet Oncology by Beer et...
Comorbidity and Prostate Cancer–Specific and Other-Cause Mortality
A Swedish population-based observational study has shown that comorbidity is a significant factor in other-cause but not prostate cancer–specific mortality after adjustment for patient, tumor, and treatment factors among men with prostate cancer. The findings were reported in the Journal of...
Alzheimer’s Disease Risk in Medicare Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer
As reported by Baik et al in the Journal of Clinical Oncology, Medicare patients who received androgen-deprivation therapy for prostate cancer do not appear to be at increased risk for Alzheimer’s disease and may have an extremely small increased risk for dementia. Study Details The study...
Postdiagnosis Statin Use and Mortality in Prostate Cancer
As reported by Larsen et al in the Journal of Clinical Oncology, a Danish retrospective study has shown reduced cancer-specific and all-cause mortality with postdiagnosis statin use in patients with prostate cancer. Study Details The study involved nationwide Danish registry data from 31,790...
Metastasis-Free Survival as Surrogate for Overall Survival in Localized Prostate Cancer
In a meta-analysis reported in the Journal of Clinical Oncology, Xie et al found that metastasis-free survival was a strong surrogate for overall survival in patients with localized prostate cancer, potentially providing a metric that could accelerate assessment of new adjuvant therapy approaches. ...
Reduced-Dose Cabazitaxel After Docetaxel in Metastatic Castration-Resistant Prostate Cancer
In the phase III PROSELICA trial reported by Eisenberger et al in the Journal of Clinical Oncology, a cabazitaxel (Jevtana) dose of 20 mg/m2 (C20) was noninferior for overall survival vs the currently recommended dose of 25 mg/m2 (C25) after docetaxel treatment in metastatic castration-resistant...
First-Line Cabazitaxel vs Docetaxel in Metastatic Castration-Resistant Prostate Cancer
The phase III FIRSTANA trial has shown no difference in overall survival with two dose regimens of cabazitaxel (Jevtana) vs docetaxel in the first-line treatment of metastatic castration-resistant prostate cancer. Results were reported by Oudard et al in the Journal of Clinical Oncology....
Health-Related Quality of Life With Immediate vs Delayed ADT in Prostate Cancer
In a health-related quality-of-life study among patients in the phase III TOAD trial, immediate vs delayed androgen-deprivation therapy was associated with early worsening of androgen-deprivation therapy–related symptoms but few other comparative adverse effects on functioning or quality of...
Adverse Pathologic Findings in Low-Volume Intermediate-Risk Prostate Cancer
In a single-center analysis reported in JAMA Oncology, Patel et al found that among men undergoing elective radical prostatectomy, those with low-volume intermediate-risk disease had significantly higher rates of adverse pathologic findings compared than did those with very low-risk and low-risk...
Comparison of Circulating Tumor DNA and Metastatic Tissue Biopsy in Identifying Mutations in Prostate Cancer
In a study reported in the Journal of the National Cancer Institute, Wyatt et al found high agreement between driver mutations in plasma circulating tumor DNA (ctDNA) and metastatic tissue biopsy in castration-resistant prostate cancer. Mutations Identified in ctDNA In the study, targeted...
Association Between Vasectomy and Prostate Cancer
A systematic review and meta-analysis has found no association between vasectomy and high-grade, advanced, or fatal prostate cancer but a weak association with any prostate cancer. These findings were reported in JAMA Oncology by Bhindi et al. Study Details The analysis involved 53 studies,...
Surgery vs Observation in Localized Prostate Cancer: Long-Term Follow-up of PIVOT Trial
After 19.5 years of follow-up in the PIVOT trial, radical prostatectomy was not associated with significantly improved all-cause or prostate cancer mortality vs observation among men with localized prostate cancer. The long-term follow-up data were reported in The New England Journal of Medicine by ...
T2:ERG and PCA3 RNA Urinary Testing for Detecting Aggressive Prostate Cancer
Combined testing for urinary PCA3 and TMPRSS2:ERG (T2:ERG) RNA may increase accuracy in identifying the risk for aggressive early prostate cancer, according to a study reported in JAMA Oncology by Sanda et al in the EDRN-PCA3 Study Group. Study Details The study involved 516 development cohort...
LATITUDE Trial: Adding Abiraterone and Prednisone to Androgen-Deprivation Therapy in Metastatic Castration-Sensitive Prostate Cancer
As reported in the Plenary Session at the 2017 ASCO Annual Meeting and in The New England Journal of Medicine by Fizazi et al, the phase III LATITUDE trial has shown that the addition of abiraterone acetate (Zytiga) and prednisone to androgen-deprivation therapy resulted in marked improvements in...
Clinical Implications of Luminal and Basal Subtyping of Prostate Cancer
As reported by Zhao et al in JAMA Oncology, luminal B prostate cancers carry a worse overall prognosis than luminal A and basal-like cancers, but luminal B tumors respond better to postoperative androgen-deprivation therapy. Study Details In the study, the PAM50 classifier was used to subtype...
ASCO Provisional Clinical Opinion: Second-Line Hormonal Therapy for Chemotherapy-Naive Castration-Resistant Prostate Cancer
As reported by Katherine S. Virgo, PhD, MBA, of Emory University, and colleagues in the Journal of Clinical Oncology, ASCO has issued a provisional clinical opinion on second-line hormonal therapy for chemotherapy-naive castration-resistant prostate cancer. The provisional clinical opinion applies...
Predicting Metastatic Disease After Radical Prostatectomy
An individual patient-level meta-analysis has shown that the Decipher® (GenomeDx) genomic classifier is capable of distinguishing risk groups for metastatic disease after radical prostatectomy for prostate cancer. The study was reported by Spratt and colleagues in the Journal of Clinical...
Hypofractionated vs Conventional Radiotherapy for Localized Prostate Cancer
Hypofractionated radiotherapy was noninferior to standard radiotherapy in biochemical-clinical failure disease-free survival in men with localized prostate cancer, according to a study reported by Catton et al in the Journal of Clinical Oncology. Study Details In the trial, 1,206 patients with...
Celecoxib or Celecoxib/Zoledronic Acid in Men Initiating Hormone Therapy for Prostate Cancer
As reported by Mason et al in the Journal of Clinical Oncology, long-term survival results of the UK-based, multiarm, multistage platform–design STAMPEDE trial showed no survival benefit with the addition of celecoxib or celecoxib plus zoledronic acid in men initiating long-term hormone...
Testosterone Replacement Therapy and Risk of Prostate Cancer
In a Swedish study reported in the Journal of Clinical Oncology, Loeb et al found that use of testosterone replacement therapy was not associated with an increased risk of prostate cancer and was associated with a lower risk of aggressive cancer among men developing the disease. Study Details The ...
Antisense Oligonucleotide Custirsen Combined With Docetaxel and Prednisone in Metastatic Prostate Cancer
In the phase III SYNERGY trial reported in The Lancet Oncology, Chi et al found that the addition of the second-generation antisense oligonucleotide custirsen to docetaxel and prednisone did not improve overall survival in patients with metastatic castration-resistant prostate cancer. Custirsen...
European Cohort Study of Vasectomy and Prostate Cancer Risk
In a large European cohort study reported in the Journal of Clinical Oncology, Smith Byrne et al found that vasectomy was not associated with an increased overall risk of prostate cancer or death from prostate cancer but appeared to increase the risk of lower-grade disease. Other studies have...
Use of Evidence-Based Prostate Cancer Imaging in an Integrated Health-Care System
In a study reported in the Journal of Oncology Practice, Salloum et al found that use of nonindicated imaging for diagnostic staging of low-risk prostate cancer in a nonprofit integrated health-care system remained common but has decreased in frequency. As noted by the authors: “The overuse...
Low Prostate Cancer–Specific Mortality in Men With Benign Initial Transrectal Ultrasound–Guided Biopsy Sets
In a Danish study reported in The Lancet Oncology, Klemann et al found a low risk of prostate cancer–specific mortality in men with benign initial transrectal ultrasound-guided biopsy sets. The risk was particularly low among those with lower prostate-specific antigen (PSA) levels. Study...
Adding Antiandrogen Therapy to Radiation Therapy in Recurrent Prostate Cancer
As reported in The New England Journal of Medicine by Shipley et al in the NRG Oncology Radiation Therapy Oncology Group (RTOG), the final analysis of the phase III RTOG 9601 trial showed that the addition of antiandrogen therapy with bicalutamide to radiation therapy significantly improves overall ...
Benefits of Multiparametric Magnetic Resonance Imaging in Clinically Significant Prostate Cancer
In the UK PROMIS study reported in The Lancet, Ahmed et al found that use of multiparametric magnetic resonance imaging (MP-MRI) might reduce the need for transrectal ultrasound (TRUS)-guided prostate biopsy and may improve detection of clinically significant prostate cancer. Study Details In the ...
Potential Surrogate for All-Cause Mortality Risk in Localized Unfavorable-Risk Prostate Cancer
In a study reported in JAMA Oncology, Royce et al found that a prostate-specific antigen (PSA) nadir > 0.5 ng/mL may be a dominant risk factor for all-cause mortality after radiation therapy and androgen-deprivation therapy in men with localized unfavorable-risk prostate cancer. Study Details...
Vascular-Targeted Photodynamic Therapy Shows Promise in Low-Risk Prostate Cancer
In a European phase III trial reported in The Lancet Oncology, Azzouzi et al found that padeliporfin vascular-targeted photodynamic therapy was associated with a reduced rate of disease progression vs active surveillance in men with low-risk prostate cancer. Study Details In the open-label trial, ...
Does Androgen-Deprivation Therapy Increase the Risk for Dementia in Patients With Prostate Cancer?
In a UK population–based study reported in the Journal of Clinical Oncology, Khosrow-Khavar et al found no significant association between the use of androgen-deprivation therapy and the risk for dementia in patients with prostate cancer. The study involved a cohort of 30,903 men with newly...
Can Mindfulness-Based Cognitive Therapy Reduce Distress in Patients With Advanced Prostate Cancer?
Chambers et al found that a mindfulness-based cognitive therapy intervention did not improve measures of distress or anxiety vs minimally enhanced usual care among men with advanced prostate cancer, according to an Australian study reported in the Journal of Clinical Oncology. In the study, 189...
Adulthood BMI Increases Leading to Obesity Seem to Be Linked to an Increased Risk of Fatal Prostate Cancer
In a study of data from men in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial reported in the Journal of the National Cancer Institute, Kelly et al found that body mass index (BMI) increases during adulthood that lead to obesity are associated with an increased risk of...
Potential Link Between Androgen-Deprivation Therapy for Prostate Cancer and Risk for Dementia
In a single-center analysis reported in JAMA Oncology, Nead et al found that the use of androgen-deprivation therapy for prostate cancer was associated with an increased risk for dementia. The study involved electronic medical record data from the Stanford University Health System from 1994 to...
24-Gene Predictor of Response to Postoperative Radiotherapy in Prostate Cancer
In a matched retrospective analysis reported in The Lancet Oncology, Zhao et al identified and validated a 24-gene predictor of response to postoperative radiotherapy in prostate cancer. The analysis involved data from patients from five published U.S. studies (cohort, case-cohort, and...
Study Finds PFS Benefit, but No Overall Survival Benefit, for Ipilimumab in Metastatic Castration-Resistant Prostate Cancer
Ipilimumab (Yervoy) was associated with prolonged progression-free survival—but not overall survival—compared with placebo in men with asymptomatic or minimally symptomatic chemotherapy-naive metastatic castration-resistant prostate cancer without visceral metastases, according to a...
Long-Term Effects of Finasteride in Patients From the Prostate Cancer Prevention Trial
In a study reported in the Journal of the National Cancer Institute, Unger et al found that use of finasteride vs placebo in the Prostate Cancer Prevention Trial was associated with a modestly increased risk of depression and a modestly reduced risk of procedures for benign prostatic...
Study Reports No Association Between Vasectomy and Prostate Cancer Incidence or Mortality
In an analysis of the Cancer Prevention Study II (CPS-II) study cohort reported in the Journal of Clinical Oncology, Jacobs et al found no significant association between vasectomy and overall prostate cancer incidence or mortality. A recent prospective study had shown an association of vasectomy...
Patient-Reported Outcomes After Active Monitoring, Surgery, or Radiotherapy in PSA-Detected Localized Prostate Cancer
Patient-reported outcomes differed among men with localized prostate cancer detected by prostate-specific antigen (PSA) testing who were randomized to receive active monitoring, surgery, or radiotherapy in the UK ProtecT trial, according to a report by Donovan et al in The New England Journal of...
